IgA Nephropathy

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.

Barratt discusses the potential of targeting the alternative pathway for controlling inflammation and the significance of the new APPLAUSE-IgAN data.

RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.

Results suggest low-dose corticosteroids in combination with leflunomide are more efficacious for improving urine protein excretion with better safety than full-dose corticosteroids.

Our March 2024 month in review highlights HCPLive’s top coverage of the latest news in nephrology, ranging from new CKD research and KDIGO guidelines to recent IgAN data.

Both high blood pressure and triglycerides were identified as risk factors for IgAN, although high blood pressure was deemed to have the most direct influence.

Findings underscore the importance of considering both the serum IgA/C3 ratio and glomerular C3 staining in the management and treatment of IgAN.

Urinary miR-92a-3p, miR-425-5p, and miR-185-5p were significantly increased in patients with IgAN and were all associated with tubular atrophy/interstitial fibrosis.

Findings reveal a 20% mortality rate in an Eastern European cohort, primarily due to cardiovascular diseases and linked to an absence of RASi use, among other factors.

Use of corticosteroids with supportive therapy reduced proteinuria but was associated with adverse effects and did not impact time to ESKD versus supportive therapy alone.

Our February 2024 month in review spotlights news in IgAN identification and management as well as recent research about various factors impacting renal care outcomes in different patient populations.

Results identified mesangial IgM deposition as an independent risk factor for ESKD in patients with IgAN, particularly in advanced disease stages.

The incidence of KRT for primary glomerular disease-induced kidney failure was greatest for IgA nephropathy and focal segmental glomerulosclerosis.

Results confirmed the cost-effectiveness of Japan’s mandated school urinary screening strategy, also pointing to fewer patients progressing to ESKD compared to no screening.

A distinctive gene expression profile was identified in patients with IgA nephropathy using NanoString mRNA technology, suggesting inflammatory and fibrotic targets in the disease.

Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.

Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.

Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.

The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators

Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.

Findings from the retrospective cohort study suggest an increased prevalence of advanced kidney disease among individuals with Crohn disease and ulcerative colitis.

Geovanni Faddoul, MD, discusses findings from his recent study examining the impact of induction and maintenance therapy on IgAN recurrence, graft survival, and mortality in kidney transplantation.

Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.

Renal failure risk group classification based on pathological findings from patients’ kidney biopsy, eGFR, and proteinuria was significantly associated with a composite 50% increase in serum creatinine.

Findings suggest serum C3 may be a viable biomarker for the occurrence and prognosis of IgAN, highlighting the role of the complement system in the disease’s pathogenesis.

Results of the retrospective study suggested blood pressure, serum IgA, potassium, and segmental glomerulosclerosis may be predictive of the rapid progression of renal endpoints in patients with concurrent IgAN and membranous nephropathy.